Free shipping on all orders over $ 500

Tisotumab Vedotin

Cat. No. M40543

All AbMole products are for research use only, cannot be used for human consumption.

Tisotumab Vedotin Structure
Size Price Availability Quantity
100ug USD 490 In stock
1mg USD 990 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer.

Chemical Information
CAS Number 1418731-10-8
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Xin Song et al. Drugs Today (Barc). Tisotumab vedotin for the treatment of cervical carcinoma

[2] No authors listed. Am J Health Syst Pharm. Tisotumab Vedotin-tftv

[3] Anthony Markham. Drugs. Tisotumab Vedotin: First Approval

[4] Robert L Coleman et al. Lancet Oncol. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Related Antibody-Drug Conjugates (ADCs) Products
Talacotuzumab-MMAE

Talacotuzumab-MMAE is an antibody-drug conjugate (ADC) targeting IL-3Ra / CD123. Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody.

Enfortumab vedotin-ejfv

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker.

Vandortuzumab vedotin

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

Farletuzumab MMAE

Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE.

Zilovertamab vedotin

Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tisotumab Vedotin supplier, Antibody-Drug Conjugates (ADCs), inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.